Previous studies have shown that simultaneous targeting of EGFR, HER2, and HER3 with multispecific antibodies can prevent compensatory tumor promoting mechanisms within the HER family, providing a scientific rationale for the development of a pan-HER antibody (29). This evidence concerns the gene ERBB3 and neoplasm.